跳至主要内容
临床试验/NCT03013803
NCT03013803已完成不适用

Acceptability Study on Nutricomp® Drink Plus Fibre in Adults

B. Braun Melsungen AG1 个研究点 分布在 1 个国家目标入组 19 人开始时间: 2016年12月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
19
试验地点
1
主要终点
Occurrence of gastrointestinal tolerance parameters

研究概览

简要总结

Required for Advisory Committee for Borderline Substances (ACBS) approval. Aim of this study is to access the palatability, compliance and GI-tolerance of Nutricomp® Drink Plus Fibre to show that it is acceptable for patients in the United Kingdom.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Male and female participants ≥ 18 years of age
  • •Assessed to have malnutrition or be at risk of malnutrition by a Dietician within the investigator team. Assessment to include, but not limited to weight loss history, current BMI/MUST score, anamnesis, dietary intake history and predicted future oral intake.
  • •Anticipated period of nutritional support ≥ 12 days
  • •Patient has the capacity and is willing to provide informed consent.

排除标准

  • •Participants with mental in capabilities who are unable to give informed consent
  • •Hypersensitivity to any of the active substances or excipients within the IP
  • •Severely impaired gastrointestinal function or complete failure
  • •More than 50% of nutrition from Parenteral Nutrition
  • •Simultaneous participation in another interventional study
  • •Participants who are unwilling or mentally and/or physically unable to adhere to study procedures
  • •Participants with dysphagia requiring thickened fluids
  • •Participants with significant renal impairment (CKD)
  • •Pregnancy

研究组 & 干预措施

Nutricomp Drink Plus Fibre

Experimental

Nutricomp® Drink Plus Fibre (flavours vanilla, coffee, peach-apricot and chocolate)

干预措施: Nutricomp Drink Plus Fibre (Dietary Supplement)

结局指标

主要结局

Occurrence of gastrointestinal tolerance parameters

时间窗: Day 1 - day 13

次要结局

  • Occurrence of (further) adverse events during the treatment period (yes/no, if yes timing/duration/assumed cause/seriousness/severity)(Day 1 - day 13)
  • Palatability evaluation performed under controlled condition using a questionnaire with a 5 point hedonic scale rang(Day 1 - day 13)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验